Background The optimal upper limit of the normal range for prostate-specific antigen (PSA)
is unknown. We investigated the prevalence of prostate cancer among men in the Prostate …

Background Androgens are involved in the development of prostate cancer. Finasteride, an
inhibitor of 5α-reductase, inhibits the conversion of testosterone to dihydrotestosterone, the …

Context Secondary analyses of 2 randomized controlled trials and supportive epidemiologic
and preclinical data indicated the potential of selenium and vitamin E for preventing …

Context The initial report of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
found no reduction in risk of prostate cancer with either selenium or vitamin E supplements …

In 2009, the American Cancer Society (ACS) Prostate Cancer Advisory Committee began
the process of a complete update of recommendations for early prostate cancer detection. A …

Purpose : Extraprostatic disease will be manifest in a third of men after radical prostatectomy.
We present the long-term followup of a randomized clinical trial of radiotherapy to reduce …

Demographic data clearly demonstrate that the percentage of the population in the older
age group is increasing. Androgen deficiency in the aging male has become a topic of …

Background The cardiovascular safety of testosterone-replacement therapy in middle-aged
and older men with hypogonadism has not been determined. Methods In a multicenter, …

Background: Prostate-specific antigen (PSA) testing is the primary method used to diagnose
prostate cancer in the United States. Methods to integrate other risk factors associated with …

Background Combined androgen blockade for the treatment of metastatic prostate cancer
consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the …